NECT is next: Implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness

by Yun O, Priotto G, Tong J, Flevaud L, Chappuis F. PLoS Negl Trop Dis, May 2010, 4(5):e720.

Summary: In April 2009, a new treatment option for second-stage T. b. gambiense HAT, nifurtimox-eflornithine combination therapy (NECT), was added to the WHO Essential Medicines List (EML). In the current context, NECT stands as the most promising first-line treatment for second-stage T. b. gambiense HAT. The article describes the developments and challenges in rolling out and implementing NECT in HAT-endemic areas.

Click here to read the article